Cargando…

Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients

AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozcan, Ilke, Toya, Takumi, Corban, Michel T., Ahmad, Ali, Lerman, Lilach O., Kushwaha, Sudhir S., Lerman, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712915/
https://www.ncbi.nlm.nih.gov/pubmed/34510802
http://dx.doi.org/10.1002/ehf2.13610
_version_ 1784623663367061504
author Ozcan, Ilke
Toya, Takumi
Corban, Michel T.
Ahmad, Ali
Lerman, Lilach O.
Kushwaha, Sudhir S.
Lerman, Amir
author_facet Ozcan, Ilke
Toya, Takumi
Corban, Michel T.
Ahmad, Ali
Lerman, Lilach O.
Kushwaha, Sudhir S.
Lerman, Amir
author_sort Ozcan, Ilke
collection PubMed
description AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation. METHODS AND RESULTS: We included 66 transplant patients who underwent serial IVUS surveillance for CAV and baseline assessment of peripheral endothelial function using reactive hyperaemia peripheral arterial tonometry. PED was defined as reactive hyperaemia index < 2. The primary endpoint of the study was to investigate the association of PED with CAV progression assessed by intravascular ultrasound (IVUS). CAV progression was assessed as the change (Δ) in plaque volume divided by segment length, and Δ plaque index (plaque volume/vessel volume), adjusted for the time between IVUS measurements (median 3.0 [2.2, 3.1] years). The secondary endpoint was to investigate the association between PED and future MACE, which was defined as any incident of revascularization, heart failure hospitalization, stroke, myocardial infarction, re‐transplantation, and death. Patients with PED (n = 27) had more yearly plaque progression (0.50 ± 0.66 vs. 0.15 ± 0.50 mm(3)/mm/year, P = 0.02) and a higher Δ plaque index (2.41 ± 2.53% vs. 0.69 ± 2.22%, P = 0.01). Patients with PED were more likely to experience MACE during a median follow‐up of 8.2 years (interquartile range [7.6, 8.4]), after adjustment for potential cofounders such as age, high‐density lipoprotein cholesterol levels, total rejection score, baseline International Society for Heart & Lung Transplantation CAV grade, and indication of transplantation. (hazard ratio 2.15, 95% confidence interval [1.09, 4.23], P = 0.03). CONCLUSIONS: Peripheral endothelial dysfunction is associated with increased plaque progression and adverse long‐term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation.
format Online
Article
Text
id pubmed-8712915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87129152022-01-04 Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients Ozcan, Ilke Toya, Takumi Corban, Michel T. Ahmad, Ali Lerman, Lilach O. Kushwaha, Sudhir S. Lerman, Amir ESC Heart Fail Original Articles AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation. METHODS AND RESULTS: We included 66 transplant patients who underwent serial IVUS surveillance for CAV and baseline assessment of peripheral endothelial function using reactive hyperaemia peripheral arterial tonometry. PED was defined as reactive hyperaemia index < 2. The primary endpoint of the study was to investigate the association of PED with CAV progression assessed by intravascular ultrasound (IVUS). CAV progression was assessed as the change (Δ) in plaque volume divided by segment length, and Δ plaque index (plaque volume/vessel volume), adjusted for the time between IVUS measurements (median 3.0 [2.2, 3.1] years). The secondary endpoint was to investigate the association between PED and future MACE, which was defined as any incident of revascularization, heart failure hospitalization, stroke, myocardial infarction, re‐transplantation, and death. Patients with PED (n = 27) had more yearly plaque progression (0.50 ± 0.66 vs. 0.15 ± 0.50 mm(3)/mm/year, P = 0.02) and a higher Δ plaque index (2.41 ± 2.53% vs. 0.69 ± 2.22%, P = 0.01). Patients with PED were more likely to experience MACE during a median follow‐up of 8.2 years (interquartile range [7.6, 8.4]), after adjustment for potential cofounders such as age, high‐density lipoprotein cholesterol levels, total rejection score, baseline International Society for Heart & Lung Transplantation CAV grade, and indication of transplantation. (hazard ratio 2.15, 95% confidence interval [1.09, 4.23], P = 0.03). CONCLUSIONS: Peripheral endothelial dysfunction is associated with increased plaque progression and adverse long‐term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation. John Wiley and Sons Inc. 2021-09-12 /pmc/articles/PMC8712915/ /pubmed/34510802 http://dx.doi.org/10.1002/ehf2.13610 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Ozcan, Ilke
Toya, Takumi
Corban, Michel T.
Ahmad, Ali
Lerman, Lilach O.
Kushwaha, Sudhir S.
Lerman, Amir
Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title_full Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title_fullStr Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title_full_unstemmed Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title_short Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
title_sort peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712915/
https://www.ncbi.nlm.nih.gov/pubmed/34510802
http://dx.doi.org/10.1002/ehf2.13610
work_keys_str_mv AT ozcanilke peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT toyatakumi peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT corbanmichelt peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT ahmadali peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT lermanlilacho peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT kushwahasudhirs peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients
AT lermanamir peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients